New combo therapy shows promise for inoperable lung cancer patients

NCT ID NCT02599454

Completed Disease control Sponsor: Megan Daly, MD Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times

Summary

This early-stage study tested a combination of an immunotherapy drug (atezolizumab) and precise, high-dose radiation (SBRT) in 20 people with stage I non-small cell lung cancer who could not have surgery. The main goal was to find the safest dose of atezolizumab when given with radiation and to see how well the combination worked at shrinking tumors. The approach aims to boost the immune system's ability to fight cancer while using radiation to directly kill tumor cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE I NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

David Grant United States Air Force Medical Center

Travis AFB, California, 94535-1800, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States

Conditions

Explore the condition pages connected to this study.

STAGE I NON-SMALL CELL LUNG CANCER STAGE I NON-SMALL CELL LUNG CANCER